PubRank

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Clinical Trial ID NCT00083889

PubWeight™ 72.74‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00083889

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 39.39
2 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 13.52
3 Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011 3.58
4 Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 2014 2.26
5 Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014 2.23
6 Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015 1.53
7 Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012 1.37
8 Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013 1.24
9 Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer 2010 1.13
10 A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012 1.12
11 Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 2016 1.03
12 Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011 0.97
13 Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. Eur Urol 2015 0.92
14 Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. Br J Clin Pharmacol 2016 0.91
15 Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br J Cancer 2012 0.87
16 Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 2015 0.84
17 Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. PLoS One 2014 0.83
18 Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat 2015 0.79
19 Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol 2016 0.76
20 Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget 2016 0.75
21 Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol 2016 0.75
Next 100